Immunome (IMNM) Net Cash Flow Growth (1y) (2020 - 2026)

Immunome (IMNM) Net Cash Flow Growth (1y) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCF Growth (1y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -88.82%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 301.06%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 453.08%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -125.22%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Immunome 2.49 Bn 1.91 Bn - -161.95%

Historic Data

Download Data
DateValue
Mar 31, 2026 -161.95%
Dec 31, 2025 3,217.32%
Sep 30, 2025 1,418.75%
Jun 30, 2025 -8.85%
Mar 31, 2025 -33.20%
Dec 31, 2024 -251.99%
Sep 30, 2024 -118.70%
Jun 30, 2024 -1,637.53%
Mar 31, 2024 609.70%
Dec 31, 2023 218.99%
Sep 30, 2023 789.80%
Jun 30, 2023 27.00%
Mar 31, 2023 479.54%
Dec 31, 2022 3.69%
Sep 30, 2022 -111.13%
Jun 30, 2022 -134.94%
Mar 31, 2022 -81.95%
Dec 31, 2021 -121.24%
Sep 30, 2021 -17.77%
Jun 30, 2021 176.41%